Serveur d'exploration sur l'opéra

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.

Identifieur interne : 001810 ( Main/Exploration ); précédent : 001809; suivant : 001811

Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.

Auteurs : Rodney U. Anderson [États-Unis] ; Scott Macdiarmid ; Sherron Kell ; James H. Barada ; Scott Serels ; Roger P. Goldberg

Source :

RBID : pubmed:16724169

English descriptors

Abstract

The efficacy and the tolerability of extended-release oxybutynin chloride, 10 mg daily, and extended-release tolterodine tartrate, 4 mg daily, in women with or without prior anticholinergic treatment for overactive bladder (OAB) were compared in a post-hoc analysis of data from the Overactive Bladder: Performance of Extended Release Agents (OPERA) trial. The patient population and study methods have been described previously (Diokno et al., for the OPERA Study Group, Mayo Clin Proc 78:687-695, 2003). Among the group with anticholinergic experience, extended-release oxybutynin was significantly more effective than extended-release tolterodine in reducing micturition frequency at last observation (p=0.052). Complete freedom from urge incontinence was reported by significantly more patients taking oxybutynin than tolterodine at last observation (23.6 vs 15.1%, p=0.038). In addition, among patients completing a full 12 weeks of oxybutynin treatment, significantly greater reductions were observed compared with those taking tolterodine on the primary efficacy variable, number of urge incontinence episodes (p=0.049), and the combined total of urge and non-urge episodes (p=0.012), although the differences between treatment groups were not significant at last observation. In the anticholinergic-naïve group, efficacy and tolerability outcomes were similar across treatments, except that oxybutynin was associated with a significantly lower frequency of micturition at last observation (p=0.035). No efficacy differences favoring tolterodine were observed, and tolerability of the treatments was comparable. Dry mouth (mostly mild to moderate in severity) was reported significantly more often among participants taking extended-release oxybutynin than extended-release tolterodine (32.2 vs 19.2%, p=0.004), but only among those with previous anticholinergic experience. Discontinuation rates were comparably low across groups. The results demonstrate the appropriateness of initiating treatment for OAB with extended-release oxybutynin, particularly in women presenting with incontinence.

DOI: 10.1007/s00192-005-0057-7
PubMed: 16724169


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.</title>
<author>
<name sortKey="Anderson, Rodney U" sort="Anderson, Rodney U" uniqKey="Anderson R" first="Rodney U" last="Anderson">Rodney U. Anderson</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Urology, Stanford University School of Medicine, 300 Pasteur Drive, Suite 287, Stanford, CA 94305, USA. rua@stanford.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Urology, Stanford University School of Medicine, 300 Pasteur Drive, Suite 287, Stanford, CA 94305</wicri:regionArea>
<placeName>
<region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Macdiarmid, Scott" sort="Macdiarmid, Scott" uniqKey="Macdiarmid S" first="Scott" last="Macdiarmid">Scott Macdiarmid</name>
</author>
<author>
<name sortKey="Kell, Sherron" sort="Kell, Sherron" uniqKey="Kell S" first="Sherron" last="Kell">Sherron Kell</name>
</author>
<author>
<name sortKey="Barada, James H" sort="Barada, James H" uniqKey="Barada J" first="James H" last="Barada">James H. Barada</name>
</author>
<author>
<name sortKey="Serels, Scott" sort="Serels, Scott" uniqKey="Serels S" first="Scott" last="Serels">Scott Serels</name>
</author>
<author>
<name sortKey="Goldberg, Roger P" sort="Goldberg, Roger P" uniqKey="Goldberg R" first="Roger P" last="Goldberg">Roger P. Goldberg</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="doi">10.1007/s00192-005-0057-7</idno>
<idno type="RBID">pubmed:16724169</idno>
<idno type="pmid">16724169</idno>
<idno type="wicri:Area/PubMed/Corpus">000491</idno>
<idno type="wicri:Area/PubMed/Curation">000491</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000469</idno>
<idno type="wicri:Area/Ncbi/Merge">000393</idno>
<idno type="wicri:Area/Ncbi/Curation">000393</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000393</idno>
<idno type="wicri:Area/Main/Merge">001843</idno>
<idno type="wicri:Area/Main/Curation">001810</idno>
<idno type="wicri:Area/Main/Exploration">001810</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.</title>
<author>
<name sortKey="Anderson, Rodney U" sort="Anderson, Rodney U" uniqKey="Anderson R" first="Rodney U" last="Anderson">Rodney U. Anderson</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Urology, Stanford University School of Medicine, 300 Pasteur Drive, Suite 287, Stanford, CA 94305, USA. rua@stanford.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Urology, Stanford University School of Medicine, 300 Pasteur Drive, Suite 287, Stanford, CA 94305</wicri:regionArea>
<placeName>
<region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Macdiarmid, Scott" sort="Macdiarmid, Scott" uniqKey="Macdiarmid S" first="Scott" last="Macdiarmid">Scott Macdiarmid</name>
</author>
<author>
<name sortKey="Kell, Sherron" sort="Kell, Sherron" uniqKey="Kell S" first="Sherron" last="Kell">Sherron Kell</name>
</author>
<author>
<name sortKey="Barada, James H" sort="Barada, James H" uniqKey="Barada J" first="James H" last="Barada">James H. Barada</name>
</author>
<author>
<name sortKey="Serels, Scott" sort="Serels, Scott" uniqKey="Serels S" first="Scott" last="Serels">Scott Serels</name>
</author>
<author>
<name sortKey="Goldberg, Roger P" sort="Goldberg, Roger P" uniqKey="Goldberg R" first="Roger P" last="Goldberg">Roger P. Goldberg</name>
</author>
</analytic>
<series>
<title level="j">International urogynecology journal and pelvic floor dysfunction</title>
<imprint>
<date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult</term>
<term>Aged</term>
<term>Benzhydryl Compounds (adverse effects)</term>
<term>Benzhydryl Compounds (pharmacology)</term>
<term>Cresols (adverse effects)</term>
<term>Cresols (pharmacology)</term>
<term>Demography</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Female</term>
<term>Humans</term>
<term>Mandelic Acids (adverse effects)</term>
<term>Mandelic Acids (pharmacology)</term>
<term>Middle Aged</term>
<term>Muscarinic Antagonists (adverse effects)</term>
<term>Muscarinic Antagonists (pharmacology)</term>
<term>Patient Dropouts</term>
<term>Patient Participation</term>
<term>Phenylpropanolamine (adverse effects)</term>
<term>Phenylpropanolamine (pharmacology)</term>
<term>Tolterodine Tartrate</term>
<term>Treatment Outcome</term>
<term>Urinary Bladder, Overactive (drug therapy)</term>
<term>Urinary Incontinence, Urge (drug therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Benzhydryl Compounds</term>
<term>Cresols</term>
<term>Mandelic Acids</term>
<term>Muscarinic Antagonists</term>
<term>Phenylpropanolamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Benzhydryl Compounds</term>
<term>Cresols</term>
<term>Mandelic Acids</term>
<term>Muscarinic Antagonists</term>
<term>Phenylpropanolamine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Urinary Bladder, Overactive</term>
<term>Urinary Incontinence, Urge</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adult</term>
<term>Aged</term>
<term>Demography</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Female</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Patient Dropouts</term>
<term>Patient Participation</term>
<term>Tolterodine Tartrate</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The efficacy and the tolerability of extended-release oxybutynin chloride, 10 mg daily, and extended-release tolterodine tartrate, 4 mg daily, in women with or without prior anticholinergic treatment for overactive bladder (OAB) were compared in a post-hoc analysis of data from the Overactive Bladder: Performance of Extended Release Agents (OPERA) trial. The patient population and study methods have been described previously (Diokno et al., for the OPERA Study Group, Mayo Clin Proc 78:687-695, 2003). Among the group with anticholinergic experience, extended-release oxybutynin was significantly more effective than extended-release tolterodine in reducing micturition frequency at last observation (p=0.052). Complete freedom from urge incontinence was reported by significantly more patients taking oxybutynin than tolterodine at last observation (23.6 vs 15.1%, p=0.038). In addition, among patients completing a full 12 weeks of oxybutynin treatment, significantly greater reductions were observed compared with those taking tolterodine on the primary efficacy variable, number of urge incontinence episodes (p=0.049), and the combined total of urge and non-urge episodes (p=0.012), although the differences between treatment groups were not significant at last observation. In the anticholinergic-naïve group, efficacy and tolerability outcomes were similar across treatments, except that oxybutynin was associated with a significantly lower frequency of micturition at last observation (p=0.035). No efficacy differences favoring tolterodine were observed, and tolerability of the treatments was comparable. Dry mouth (mostly mild to moderate in severity) was reported significantly more often among participants taking extended-release oxybutynin than extended-release tolterodine (32.2 vs 19.2%, p=0.004), but only among those with previous anticholinergic experience. Discontinuation rates were comparably low across groups. The results demonstrate the appropriateness of initiating treatment for OAB with extended-release oxybutynin, particularly in women presenting with incontinence.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Californie</li>
</region>
</list>
<tree>
<noCountry>
<name sortKey="Barada, James H" sort="Barada, James H" uniqKey="Barada J" first="James H" last="Barada">James H. Barada</name>
<name sortKey="Goldberg, Roger P" sort="Goldberg, Roger P" uniqKey="Goldberg R" first="Roger P" last="Goldberg">Roger P. Goldberg</name>
<name sortKey="Kell, Sherron" sort="Kell, Sherron" uniqKey="Kell S" first="Sherron" last="Kell">Sherron Kell</name>
<name sortKey="Macdiarmid, Scott" sort="Macdiarmid, Scott" uniqKey="Macdiarmid S" first="Scott" last="Macdiarmid">Scott Macdiarmid</name>
<name sortKey="Serels, Scott" sort="Serels, Scott" uniqKey="Serels S" first="Scott" last="Serels">Scott Serels</name>
</noCountry>
<country name="États-Unis">
<region name="Californie">
<name sortKey="Anderson, Rodney U" sort="Anderson, Rodney U" uniqKey="Anderson R" first="Rodney U" last="Anderson">Rodney U. Anderson</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001810 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001810 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    OperaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:16724169
   |texte=   Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:16724169" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a OperaV1 

Wicri

This area was generated with Dilib version V0.6.21.
Data generation: Thu Apr 14 14:59:05 2016. Site generation: Thu Oct 8 06:48:41 2020